Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results

被引：3

作者：

Mitsunaga, Shuichi

Ikeda, Masafumi

Ueno, Hideki

Nakachi, Kohei

Morizane, Chigusa

Kondo, Shunsuke

Shimizu, Satoshi

Kojima, Yasushi

Suzuki, Takuya

Tamai, Toshiyuki

O'Brien, James P.

Okusaka, Takuji

机构：

[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[2] Natl Canc Ctr, Tokyo, Japan

[3] Natl Ctr Global Hlth & Med, Tokyo, Japan

[4] Eisai, Tokyo, Japan

[5] Eisai, Woodcliff Lake, NJ USA

来源：

关键词：

D O I：

10.1200/jco.2013.31.4_suppl.231

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

231

引用

页数：1